BR100 Increased By (0.75%)
BR30 Increased By (0.57%)
KSE100 Increased By (0.65%)
KSE30 Increased By (0.66%)
AGHA 7.77 Increased By ▲ 0.02 (0.26%)
BECO 5.20 Increased By ▲ 0.01 (0.19%)
BML 57.60 Decreased By ▼ -1.06 (-1.81%)
BOP 34.26 Increased By ▲ 0.57 (1.69%)
CNERGY 10.92 Increased By ▲ 0.31 (2.92%)
CSIL 5.43 Increased By ▲ 0.13 (2.45%)
FCCL 54.65 Increased By ▲ 0.91 (1.69%)
FFL 16.67 Increased By ▲ 0.21 (1.28%)
FNEL 1.25 Increased By ▲ 0.03 (2.46%)
KEL 7.37 Increased By ▲ 0.09 (1.24%)
KOSM 5.77 Increased By ▲ 0.13 (2.3%)
LOTCHEM 29.76 Increased By ▲ 0.11 (0.37%)
MLCF 95.85 Decreased By ▼ -0.51 (-0.53%)
NBP 204.75 Increased By ▲ 1.22 (0.6%)
NCPL 57.71 Increased By ▲ 0.86 (1.51%)
NPL 69.44 Increased By ▲ 2.13 (3.16%)
OGDC 318.40 Increased By ▲ 0.18 (0.06%)
PACE 10.82 Increased By ▲ 0.19 (1.79%)
PAEL 43.05 Increased By ▲ 1.28 (3.06%)
PIBTL 16.85 Increased By ▲ 0.04 (0.24%)
PPL 221.20 Increased By ▲ 1.03 (0.47%)
PRL 51.90 Increased By ▲ 2.85 (5.81%)
PTC 71.00 Increased By ▲ 0.99 (1.41%)
SSGC 29.14 No Change ▼ 0.00 (0%)
TBL 9.95 Increased By ▲ 0.18 (1.84%)
TELE 8.85 Increased By ▲ 0.03 (0.34%)
TPL 17.69 Increased By ▲ 0.52 (3.03%)
TPLP 12.91 Increased By ▲ 0.40 (3.2%)
TREET 22.81 Increased By ▲ 0.22 (0.97%)
TRG 60.10 Decreased By ▼ -0.12 (-0.2%)

The Competition Commission of Pakistan (CCP) has approved the acquisition of a certain shareholding in Route2Health (Private) Limited by the UAE-based AZT Foundation, the regulator said on Friday.

According to the CCP, the shares will be acquired from Tausif Ahmad Khan, Zainub Abbas, and Javaid Hussain under a Share Purchase Agreement.

AZT Foundation was established to hold and manage assets on behalf of the sellers. Route2Health, a Pakistan-based company, operates in the manufacturing, marketing, and distribution of nutraceuticals and health supplements.

CCP clears acquisition of shareholding in Heavy Electrical Complex

The CCP said it carried out a detailed competitive assessment and identified the relevant product market as “nutraceutical and herbal supplements.” It noted that the deal qualified as a conglomerate merger since no horizontal or vertical overlaps exist between the buyer and the target company.

The Commission concluded that the acquisition would not create or strengthen a dominant position in the relevant market and cleared the transaction under Section 11 of the Competition Act, 2010.

Comments

Comments are closed for this article.